colo205  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC colo205
    (a) Schematic representation of the adopted methodology involved on the HTS setup. b) Z’-factor determination of HTS assay in 384-well plates considering the detection of SLeX in <t>COLO205</t> WT cells as the positive control and COLO205 ST3GalIV as the negative control. Values of Z’ higher than 0,5 allow us to proceed with confidence with the HTS assay (c) Graphic representation of SLeX detection in each well containing the different screened compounds from two distinct libraries (Prestwick® and DIVERSet®). Monensin (red circle) was one of the identified hits, according to the selection criteria (d) Graphic representation of SLeX irnmunodetection at the cell surface of COLO205 cells treated with DMSO (blue) or with different monensin concentrations ranging from O to 500 nM (red), and (e) representative images of irnmunotluorescence staining showing the reduction in SLeX irnmunodetection in the different tested monensin concentrations in a dose dependent manner. The scale bar corresponds to I00 µm. (f, g) SLeX irnmunodetection by flow cytometry in COLO205 cells (f) and KATOIII cells (g) upon treatment with DMSO (blue) or monensin (red), validated the inhibitory capacity ofmonensin in a dose-response manner. *p<0.01 vs. the DMSO-treated group.
    Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    1) Product Images from "Monensin as potential drug for treatment of SLeX-positive tumors"

    Article Title: Monensin as potential drug for treatment of SLeX-positive tumors

    Journal: medRxiv

    doi: 10.1101/2024.03.11.24304048

    (a) Schematic representation of the adopted methodology involved on the HTS setup. b) Z’-factor determination of HTS assay in 384-well plates considering the detection of SLeX in COLO205 WT cells as the positive control and COLO205 ST3GalIV as the negative control. Values of Z’ higher than 0,5 allow us to proceed with confidence with the HTS assay (c) Graphic representation of SLeX detection in each well containing the different screened compounds from two distinct libraries (Prestwick® and DIVERSet®). Monensin (red circle) was one of the identified hits, according to the selection criteria (d) Graphic representation of SLeX irnmunodetection at the cell surface of COLO205 cells treated with DMSO (blue) or with different monensin concentrations ranging from O to 500 nM (red), and (e) representative images of irnmunotluorescence staining showing the reduction in SLeX irnmunodetection in the different tested monensin concentrations in a dose dependent manner. The scale bar corresponds to I00 µm. (f, g) SLeX irnmunodetection by flow cytometry in COLO205 cells (f) and KATOIII cells (g) upon treatment with DMSO (blue) or monensin (red), validated the inhibitory capacity ofmonensin in a dose-response manner. *p<0.01 vs. the DMSO-treated group.
    Figure Legend Snippet: (a) Schematic representation of the adopted methodology involved on the HTS setup. b) Z’-factor determination of HTS assay in 384-well plates considering the detection of SLeX in COLO205 WT cells as the positive control and COLO205 ST3GalIV as the negative control. Values of Z’ higher than 0,5 allow us to proceed with confidence with the HTS assay (c) Graphic representation of SLeX detection in each well containing the different screened compounds from two distinct libraries (Prestwick® and DIVERSet®). Monensin (red circle) was one of the identified hits, according to the selection criteria (d) Graphic representation of SLeX irnmunodetection at the cell surface of COLO205 cells treated with DMSO (blue) or with different monensin concentrations ranging from O to 500 nM (red), and (e) representative images of irnmunotluorescence staining showing the reduction in SLeX irnmunodetection in the different tested monensin concentrations in a dose dependent manner. The scale bar corresponds to I00 µm. (f, g) SLeX irnmunodetection by flow cytometry in COLO205 cells (f) and KATOIII cells (g) upon treatment with DMSO (blue) or monensin (red), validated the inhibitory capacity ofmonensin in a dose-response manner. *p<0.01 vs. the DMSO-treated group.

    Techniques Used: HTS Assay, Positive Control, Negative Control, Selection, Staining, Flow Cytometry

    (a) Transmission electron microscopy (TEM) analysis, showing morphological alterations mainly at the Golgi apparatus (red arrow) and mitochondria (yellow arrow) upon monensin treatment. Images were acquired at a 12000-20000X magnification. (b) Gene ontology enrichment analysis from RNA sequencing (RNA-seq) revealing that monensin treatment led to transcriptomic alterations associated with endoplasmatic reticulum (ER) stress, protein folding and targeting to the cell membrane and adhesion. (c) Immunodetection of SLeX (left panel), and E-cadherin (right panel) in COLO205 and KATOIII cell lines upon treatment with DMSO or monensin displaying a reduction and mislocalization in SLeX and E-cadherin expression. (d) Immunotluorescence analysis of molecular makers of protein processing at cellular compartments showing alterations in the expression and localization of calnexin (ER), LMAN1 (ERGIC), Giantin (Golgi), TGN46 (TransGolgi), Tn antigen and Clathrin (endocytosis). Images were acquired at 630X magnification, and the scale bar corresponds to 10 µm. (e) Western blot analysis of SLeX expression in different cellular compartments (total, cytosolic, membrane, and secreted) in COLO205 (right) and KATOIII (left) cells treated with DMSO or monensin, demonstrating a reduction in cell membrane and secretion of SLeX-positive proteins.
    Figure Legend Snippet: (a) Transmission electron microscopy (TEM) analysis, showing morphological alterations mainly at the Golgi apparatus (red arrow) and mitochondria (yellow arrow) upon monensin treatment. Images were acquired at a 12000-20000X magnification. (b) Gene ontology enrichment analysis from RNA sequencing (RNA-seq) revealing that monensin treatment led to transcriptomic alterations associated with endoplasmatic reticulum (ER) stress, protein folding and targeting to the cell membrane and adhesion. (c) Immunodetection of SLeX (left panel), and E-cadherin (right panel) in COLO205 and KATOIII cell lines upon treatment with DMSO or monensin displaying a reduction and mislocalization in SLeX and E-cadherin expression. (d) Immunotluorescence analysis of molecular makers of protein processing at cellular compartments showing alterations in the expression and localization of calnexin (ER), LMAN1 (ERGIC), Giantin (Golgi), TGN46 (TransGolgi), Tn antigen and Clathrin (endocytosis). Images were acquired at 630X magnification, and the scale bar corresponds to 10 µm. (e) Western blot analysis of SLeX expression in different cellular compartments (total, cytosolic, membrane, and secreted) in COLO205 (right) and KATOIII (left) cells treated with DMSO or monensin, demonstrating a reduction in cell membrane and secretion of SLeX-positive proteins.

    Techniques Used: Transmission Assay, Electron Microscopy, RNA Sequencing Assay, Membrane, Immunodetection, Expressing, Western Blot

    (a) Evaluation of cell metabolism through the MTT assay in SLeX-positive (COLO205 and KATOIII) and SLeX-negative cancer cell lines (RKO, CACO-2, AGS and MKN45), showing that Monensin can significantly impact cell viability only in SLeX-positive cells (b) Proliferation rate of COLO205 and KATOIII cancer cells measured along 72h of treatment, demonstrating monensin’s inhibitory activity at higher concentrations (c) Cell death of COLO205 and KATOIII cancer cells treated with monensin for 72h, showing increased cell death mostly in KATOIII cells. (d) Wound healing (Left) and invasion (Right) assays, showing monensin’s ability to reduce COLO205 and KATOill migratory and invasive properties. (e) Schematic representation of the workflow adopted for the in vivo study of monensin impact on tumor formation and invasion using the chick chorioallantoic membrane (CAM) model. (f) Measurement of COLO205 derived xenografted tumor area, showing the development of smaller tumors by monensin-treated cancer cells (Righ) when compared to DMSO (Left). All results are presented as mean ± SEM of at least three independent experiments. *p<0.01 vs. the DMSO-treated group. (g) Number of invading xenografted COLO205 derived tumors, showing monensin’s ability to efficiently reduce tumor cell invasion when compared to DMSO-treated cells. (h) Representative images of immunohistochemical analysis of CAMs, including Hematoxilin & Eosin (H&E) staining, and human cytokeratin and SLeX immunodetection. Cytokeratin immunostaining dispicting the reduced invasive capacity of Monensin-treated cells in the chicken membrane, concomitant with reduced SLeX expression.
    Figure Legend Snippet: (a) Evaluation of cell metabolism through the MTT assay in SLeX-positive (COLO205 and KATOIII) and SLeX-negative cancer cell lines (RKO, CACO-2, AGS and MKN45), showing that Monensin can significantly impact cell viability only in SLeX-positive cells (b) Proliferation rate of COLO205 and KATOIII cancer cells measured along 72h of treatment, demonstrating monensin’s inhibitory activity at higher concentrations (c) Cell death of COLO205 and KATOIII cancer cells treated with monensin for 72h, showing increased cell death mostly in KATOIII cells. (d) Wound healing (Left) and invasion (Right) assays, showing monensin’s ability to reduce COLO205 and KATOill migratory and invasive properties. (e) Schematic representation of the workflow adopted for the in vivo study of monensin impact on tumor formation and invasion using the chick chorioallantoic membrane (CAM) model. (f) Measurement of COLO205 derived xenografted tumor area, showing the development of smaller tumors by monensin-treated cancer cells (Righ) when compared to DMSO (Left). All results are presented as mean ± SEM of at least three independent experiments. *p<0.01 vs. the DMSO-treated group. (g) Number of invading xenografted COLO205 derived tumors, showing monensin’s ability to efficiently reduce tumor cell invasion when compared to DMSO-treated cells. (h) Representative images of immunohistochemical analysis of CAMs, including Hematoxilin & Eosin (H&E) staining, and human cytokeratin and SLeX immunodetection. Cytokeratin immunostaining dispicting the reduced invasive capacity of Monensin-treated cells in the chicken membrane, concomitant with reduced SLeX expression.

    Techniques Used: MTT Assay, Activity Assay, In Vivo, Membrane, Derivative Assay, Immunohistochemical staining, Staining, Immunodetection, Immunostaining, Expressing

    colo205  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC colo205
    Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    colo205  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC colo205
    Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    colo205  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC colo205
    Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    colo205  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC colo205
    Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    human crc cell lines colo205  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC human crc cell lines colo205
    Human Crc Cell Lines Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human crc cell lines colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human crc cell lines colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    colo205  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC colo205
    Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    colo205  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC colo205
    Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    colorectal cancer cell line colo205  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC colorectal cancer cell line colo205
    Colorectal Cancer Cell Line Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colorectal cancer cell line colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colorectal cancer cell line colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    colorectal cancer cell line colo205  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC colorectal cancer cell line colo205
    Colorectal Cancer Cell Line Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colorectal cancer cell line colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colorectal cancer cell line colo205 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    ATCC colo205
    (a) Schematic representation of the adopted methodology involved on the HTS setup. b) Z’-factor determination of HTS assay in 384-well plates considering the detection of SLeX in <t>COLO205</t> WT cells as the positive control and COLO205 ST3GalIV as the negative control. Values of Z’ higher than 0,5 allow us to proceed with confidence with the HTS assay (c) Graphic representation of SLeX detection in each well containing the different screened compounds from two distinct libraries (Prestwick® and DIVERSet®). Monensin (red circle) was one of the identified hits, according to the selection criteria (d) Graphic representation of SLeX irnmunodetection at the cell surface of COLO205 cells treated with DMSO (blue) or with different monensin concentrations ranging from O to 500 nM (red), and (e) representative images of irnmunotluorescence staining showing the reduction in SLeX irnmunodetection in the different tested monensin concentrations in a dose dependent manner. The scale bar corresponds to I00 µm. (f, g) SLeX irnmunodetection by flow cytometry in COLO205 cells (f) and KATOIII cells (g) upon treatment with DMSO (blue) or monensin (red), validated the inhibitory capacity ofmonensin in a dose-response manner. *p<0.01 vs. the DMSO-treated group.
    Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colo205 - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    86
    ATCC human crc cell lines colo205
    (a) Schematic representation of the adopted methodology involved on the HTS setup. b) Z’-factor determination of HTS assay in 384-well plates considering the detection of SLeX in <t>COLO205</t> WT cells as the positive control and COLO205 ST3GalIV as the negative control. Values of Z’ higher than 0,5 allow us to proceed with confidence with the HTS assay (c) Graphic representation of SLeX detection in each well containing the different screened compounds from two distinct libraries (Prestwick® and DIVERSet®). Monensin (red circle) was one of the identified hits, according to the selection criteria (d) Graphic representation of SLeX irnmunodetection at the cell surface of COLO205 cells treated with DMSO (blue) or with different monensin concentrations ranging from O to 500 nM (red), and (e) representative images of irnmunotluorescence staining showing the reduction in SLeX irnmunodetection in the different tested monensin concentrations in a dose dependent manner. The scale bar corresponds to I00 µm. (f, g) SLeX irnmunodetection by flow cytometry in COLO205 cells (f) and KATOIII cells (g) upon treatment with DMSO (blue) or monensin (red), validated the inhibitory capacity ofmonensin in a dose-response manner. *p<0.01 vs. the DMSO-treated group.
    Human Crc Cell Lines Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human crc cell lines colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human crc cell lines colo205 - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    86
    ATCC colorectal cancer cell line colo205
    (a) Schematic representation of the adopted methodology involved on the HTS setup. b) Z’-factor determination of HTS assay in 384-well plates considering the detection of SLeX in <t>COLO205</t> WT cells as the positive control and COLO205 ST3GalIV as the negative control. Values of Z’ higher than 0,5 allow us to proceed with confidence with the HTS assay (c) Graphic representation of SLeX detection in each well containing the different screened compounds from two distinct libraries (Prestwick® and DIVERSet®). Monensin (red circle) was one of the identified hits, according to the selection criteria (d) Graphic representation of SLeX irnmunodetection at the cell surface of COLO205 cells treated with DMSO (blue) or with different monensin concentrations ranging from O to 500 nM (red), and (e) representative images of irnmunotluorescence staining showing the reduction in SLeX irnmunodetection in the different tested monensin concentrations in a dose dependent manner. The scale bar corresponds to I00 µm. (f, g) SLeX irnmunodetection by flow cytometry in COLO205 cells (f) and KATOIII cells (g) upon treatment with DMSO (blue) or monensin (red), validated the inhibitory capacity ofmonensin in a dose-response manner. *p<0.01 vs. the DMSO-treated group.
    Colorectal Cancer Cell Line Colo205, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/colorectal cancer cell line colo205/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    colorectal cancer cell line colo205 - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    Image Search Results


    (a) Schematic representation of the adopted methodology involved on the HTS setup. b) Z’-factor determination of HTS assay in 384-well plates considering the detection of SLeX in COLO205 WT cells as the positive control and COLO205 ST3GalIV as the negative control. Values of Z’ higher than 0,5 allow us to proceed with confidence with the HTS assay (c) Graphic representation of SLeX detection in each well containing the different screened compounds from two distinct libraries (Prestwick® and DIVERSet®). Monensin (red circle) was one of the identified hits, according to the selection criteria (d) Graphic representation of SLeX irnmunodetection at the cell surface of COLO205 cells treated with DMSO (blue) or with different monensin concentrations ranging from O to 500 nM (red), and (e) representative images of irnmunotluorescence staining showing the reduction in SLeX irnmunodetection in the different tested monensin concentrations in a dose dependent manner. The scale bar corresponds to I00 µm. (f, g) SLeX irnmunodetection by flow cytometry in COLO205 cells (f) and KATOIII cells (g) upon treatment with DMSO (blue) or monensin (red), validated the inhibitory capacity ofmonensin in a dose-response manner. *p<0.01 vs. the DMSO-treated group.

    Journal: medRxiv

    Article Title: Monensin as potential drug for treatment of SLeX-positive tumors

    doi: 10.1101/2024.03.11.24304048

    Figure Lengend Snippet: (a) Schematic representation of the adopted methodology involved on the HTS setup. b) Z’-factor determination of HTS assay in 384-well plates considering the detection of SLeX in COLO205 WT cells as the positive control and COLO205 ST3GalIV as the negative control. Values of Z’ higher than 0,5 allow us to proceed with confidence with the HTS assay (c) Graphic representation of SLeX detection in each well containing the different screened compounds from two distinct libraries (Prestwick® and DIVERSet®). Monensin (red circle) was one of the identified hits, according to the selection criteria (d) Graphic representation of SLeX irnmunodetection at the cell surface of COLO205 cells treated with DMSO (blue) or with different monensin concentrations ranging from O to 500 nM (red), and (e) representative images of irnmunotluorescence staining showing the reduction in SLeX irnmunodetection in the different tested monensin concentrations in a dose dependent manner. The scale bar corresponds to I00 µm. (f, g) SLeX irnmunodetection by flow cytometry in COLO205 cells (f) and KATOIII cells (g) upon treatment with DMSO (blue) or monensin (red), validated the inhibitory capacity ofmonensin in a dose-response manner. *p<0.01 vs. the DMSO-treated group.

    Article Snippet: AGS, CACO-2, COLO205, KATOIII and RKO were obtained from ATCC (American Type Culture Collection) and MKN45 was obtained from the Japanese Cancer Research Resources Bank.

    Techniques: HTS Assay, Positive Control, Negative Control, Selection, Staining, Flow Cytometry

    (a) Transmission electron microscopy (TEM) analysis, showing morphological alterations mainly at the Golgi apparatus (red arrow) and mitochondria (yellow arrow) upon monensin treatment. Images were acquired at a 12000-20000X magnification. (b) Gene ontology enrichment analysis from RNA sequencing (RNA-seq) revealing that monensin treatment led to transcriptomic alterations associated with endoplasmatic reticulum (ER) stress, protein folding and targeting to the cell membrane and adhesion. (c) Immunodetection of SLeX (left panel), and E-cadherin (right panel) in COLO205 and KATOIII cell lines upon treatment with DMSO or monensin displaying a reduction and mislocalization in SLeX and E-cadherin expression. (d) Immunotluorescence analysis of molecular makers of protein processing at cellular compartments showing alterations in the expression and localization of calnexin (ER), LMAN1 (ERGIC), Giantin (Golgi), TGN46 (TransGolgi), Tn antigen and Clathrin (endocytosis). Images were acquired at 630X magnification, and the scale bar corresponds to 10 µm. (e) Western blot analysis of SLeX expression in different cellular compartments (total, cytosolic, membrane, and secreted) in COLO205 (right) and KATOIII (left) cells treated with DMSO or monensin, demonstrating a reduction in cell membrane and secretion of SLeX-positive proteins.

    Journal: medRxiv

    Article Title: Monensin as potential drug for treatment of SLeX-positive tumors

    doi: 10.1101/2024.03.11.24304048

    Figure Lengend Snippet: (a) Transmission electron microscopy (TEM) analysis, showing morphological alterations mainly at the Golgi apparatus (red arrow) and mitochondria (yellow arrow) upon monensin treatment. Images were acquired at a 12000-20000X magnification. (b) Gene ontology enrichment analysis from RNA sequencing (RNA-seq) revealing that monensin treatment led to transcriptomic alterations associated with endoplasmatic reticulum (ER) stress, protein folding and targeting to the cell membrane and adhesion. (c) Immunodetection of SLeX (left panel), and E-cadherin (right panel) in COLO205 and KATOIII cell lines upon treatment with DMSO or monensin displaying a reduction and mislocalization in SLeX and E-cadherin expression. (d) Immunotluorescence analysis of molecular makers of protein processing at cellular compartments showing alterations in the expression and localization of calnexin (ER), LMAN1 (ERGIC), Giantin (Golgi), TGN46 (TransGolgi), Tn antigen and Clathrin (endocytosis). Images were acquired at 630X magnification, and the scale bar corresponds to 10 µm. (e) Western blot analysis of SLeX expression in different cellular compartments (total, cytosolic, membrane, and secreted) in COLO205 (right) and KATOIII (left) cells treated with DMSO or monensin, demonstrating a reduction in cell membrane and secretion of SLeX-positive proteins.

    Article Snippet: AGS, CACO-2, COLO205, KATOIII and RKO were obtained from ATCC (American Type Culture Collection) and MKN45 was obtained from the Japanese Cancer Research Resources Bank.

    Techniques: Transmission Assay, Electron Microscopy, RNA Sequencing Assay, Membrane, Immunodetection, Expressing, Western Blot

    (a) Evaluation of cell metabolism through the MTT assay in SLeX-positive (COLO205 and KATOIII) and SLeX-negative cancer cell lines (RKO, CACO-2, AGS and MKN45), showing that Monensin can significantly impact cell viability only in SLeX-positive cells (b) Proliferation rate of COLO205 and KATOIII cancer cells measured along 72h of treatment, demonstrating monensin’s inhibitory activity at higher concentrations (c) Cell death of COLO205 and KATOIII cancer cells treated with monensin for 72h, showing increased cell death mostly in KATOIII cells. (d) Wound healing (Left) and invasion (Right) assays, showing monensin’s ability to reduce COLO205 and KATOill migratory and invasive properties. (e) Schematic representation of the workflow adopted for the in vivo study of monensin impact on tumor formation and invasion using the chick chorioallantoic membrane (CAM) model. (f) Measurement of COLO205 derived xenografted tumor area, showing the development of smaller tumors by monensin-treated cancer cells (Righ) when compared to DMSO (Left). All results are presented as mean ± SEM of at least three independent experiments. *p<0.01 vs. the DMSO-treated group. (g) Number of invading xenografted COLO205 derived tumors, showing monensin’s ability to efficiently reduce tumor cell invasion when compared to DMSO-treated cells. (h) Representative images of immunohistochemical analysis of CAMs, including Hematoxilin & Eosin (H&E) staining, and human cytokeratin and SLeX immunodetection. Cytokeratin immunostaining dispicting the reduced invasive capacity of Monensin-treated cells in the chicken membrane, concomitant with reduced SLeX expression.

    Journal: medRxiv

    Article Title: Monensin as potential drug for treatment of SLeX-positive tumors

    doi: 10.1101/2024.03.11.24304048

    Figure Lengend Snippet: (a) Evaluation of cell metabolism through the MTT assay in SLeX-positive (COLO205 and KATOIII) and SLeX-negative cancer cell lines (RKO, CACO-2, AGS and MKN45), showing that Monensin can significantly impact cell viability only in SLeX-positive cells (b) Proliferation rate of COLO205 and KATOIII cancer cells measured along 72h of treatment, demonstrating monensin’s inhibitory activity at higher concentrations (c) Cell death of COLO205 and KATOIII cancer cells treated with monensin for 72h, showing increased cell death mostly in KATOIII cells. (d) Wound healing (Left) and invasion (Right) assays, showing monensin’s ability to reduce COLO205 and KATOill migratory and invasive properties. (e) Schematic representation of the workflow adopted for the in vivo study of monensin impact on tumor formation and invasion using the chick chorioallantoic membrane (CAM) model. (f) Measurement of COLO205 derived xenografted tumor area, showing the development of smaller tumors by monensin-treated cancer cells (Righ) when compared to DMSO (Left). All results are presented as mean ± SEM of at least three independent experiments. *p<0.01 vs. the DMSO-treated group. (g) Number of invading xenografted COLO205 derived tumors, showing monensin’s ability to efficiently reduce tumor cell invasion when compared to DMSO-treated cells. (h) Representative images of immunohistochemical analysis of CAMs, including Hematoxilin & Eosin (H&E) staining, and human cytokeratin and SLeX immunodetection. Cytokeratin immunostaining dispicting the reduced invasive capacity of Monensin-treated cells in the chicken membrane, concomitant with reduced SLeX expression.

    Article Snippet: AGS, CACO-2, COLO205, KATOIII and RKO were obtained from ATCC (American Type Culture Collection) and MKN45 was obtained from the Japanese Cancer Research Resources Bank.

    Techniques: MTT Assay, Activity Assay, In Vivo, Membrane, Derivative Assay, Immunohistochemical staining, Staining, Immunodetection, Immunostaining, Expressing